CALGARY, AB, Dec. 12, 2022 /CNW/ – Decibel Cannabis Company Inc. (the “Company” or “Decibel”) (TSXV: DB) (OTCQB: DBCCF), a premium cannabis producer, is pleased to announce the results of its annual general meeting of shareholders held on December 9, 2022 (the  “Meeting”).

Results of the Meeting

Decibel’s shareholders approved all matters submitted by the Company for consideration at the Meeting.

At the Meeting, Decibel’s shareholders:

Subsequent to the Meeting, Mr. Dym has been appointed and agreed to serve as the Company’s Chairman, and each of Nadia Vattovaz and Jakob Ripshtein have been appointed and agreed to serve, respectively, as chair of the Company’s Audit Committee and of its Governance, Compensation and Nominating Committee.

Message from Chairman & CEO

Decibel shareholders have elected a new board of directors to steward our next phase of growth. The experience, proven skillset and pedigree of the new board is tailored for Decibel and the internal and external feedback has been exceptionally positive.  Their success in the cannabis industry, consumer packaged goods and capital markets, now applied to Decibel, will help the business achieve its objective of becoming a leading Canadian LP – this is a very exciting moment for all of us.

Already, Decibel’s operating and commercial accomplishments have been remarkable, generating revenue growth of 39% over the first three quarters of 2022. Equally impressive has been Decibel’s ability to grow its market share from 3.3% in November 2021 to 5.9% in 2022, making Decibel the fifth largest LP ranked by market share.¹ We expect that this growth will continue as Decibel remains focused on its proven planning, execution and dedication to our products and consumers.

Despite our strong operating performance, we do not believe these results have been reflected in our share price. The cannabis sector, including Decibel, has had a difficult time attracting interest and generating value in the capital markets. While we have fared better than most other Canadian LPs, we recognize that creating shareholder value is a top priority and our new board will bring added focus to that accountability.

We believe the cannabis capital markets will shift away from valuing LPs based on the size of capacity and supply, and instead assign appropriate value to demonstrated demand for products, profitable market share and operating profit. Decibel’s performance in these areas make it a leading Canadian LP.

Ultimately, winning in the consumer market will drive strong operational results which will, in turn, lead to winning in the capital markets. Decibel believes this will attract the recognition and market value that winners are awarded.

We thank our shareholders for their confidence and patience. We also wish to extend our gratitude to the past directors while welcoming the new board of directors with enthusiasm and excitement about Decibel’s bright future.

Paul Wilson, CEO
Shawn Dym, Chairman

About Decibel

Decibel is uncompromising in the process and craftsmanship needed to deliver the highest quality cannabis products and retail experiences. Decibel has three operating production houses along with its wholly owned retail business, Prairie Records. The Qwest Estate in Creston, BC is a licensed and operating 26,000 square foot cultivation, processing and distribution space which produces the widely championed, rare cultivar-focused brands Qwest and Qwest Reserve, which are sold in six provinces across Canada. The Thunderchild Cultivation Facility, is a licensed and operating 80,000 square foot indoor cultivation facility in Battleford, SK. The Plant, Decibel’s extraction, processing and manufacturing facility, in Calgary, AB has 15,000 square feet of Health Canada licensed extraction and product development space. This production house will fuel the growth of our brands Qwest, Qwest Reserve, and Blendcraft, into new and innovative product formats like concentrates, vapes, edibles and beyond.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Information

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements.

In this news release, forward-looking statements relate to, among other things, Decibel’s 2022 operational outlook; expectations as to Decibel’s continued growth and expected earnings; Decibel’s expectations in regards to cannabis capital markets; Decibel’s business strategy and the expected results from the same; the Company’s ability to grow Qwest, Qwest Reserve and Blendcraft brands into new and innovative product formats, variations and its other business plans and expectations.

Forward-looking statements and FOFI (as defined herein) are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: risks relating to delays; regulatory changes and impacts; capital requirements; construction impacts; displacement requirements and unforeseen requirements resulting from the COVID-19 pandemic; the ability to obtain and maintain licences to retail cannabis products; review of the Company’s production facilities by Health Canada and maintenance of licences (including any amendments thereto) from Health Canada in respect thereof; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the labour market generally and the ability to access, hire and retain employees; general business, economic, competitive, political and social uncertainties; timing and completion of construction and expansion of the Company’s production facilities and retail locations; the risk that the Company may not remain in compliance with all of its financial covenants for the remainder of its twelve-month forecast period; and the delay or failure to receive board, regulatory or other approvals, including any approvals of the TSXV, as applicable. Many of these risks and uncertainties and additional risk factors are described in the Company’s Annual Information Form and Management’s Discussion and Analysis for the year ended December 31, 2021, which are available at www.sedar.com.

With respect to forward-looking statements and FOFI contained in this press release, Decibel has made assumptions regarding, but not limited to: Decibel’s ability to enter new markets and industry verticals; Decibel’s ability to attract, develop and retain key personnel; Decibel’s ability to raise additional capital and to execute on its expansion plans; the timelines for new product launches, Decibel’s ability to continue investing in infrastructure and implement scalable controls, systems and processes to support its growth; the impact of competition; the changes and trends in Decibel’s industry or the global economy; the Company’s ability to generate sufficient cash flow from operations and obtain financing, if needed, on acceptable terms or at all; the general economic, financial market, regulatory and political conditions in which the Company operates; the ability of the Company to ship its products and maintain supply chain stability; consumer interest in the Company’s products; anticipated and unanticipated costs; government regulation of the Company’s activities and products; the timely receipt of any required regulatory approvals; the Company’s ability to conduct operations in a safe, efficient and effective manner; the Company’s construction plans and timeframe for completion of such plans; and the changes in laws, rules, regulations, and global standards.

Any financial outlook or future oriented financial information (in each case “FOFI”) contained in this news release regarding prospective financial position, including, but not limited to: that the Company’s anticipated results and earnings, is based on reasonable assumptions about future events, including those described above, based on an assessment by management of the relevant information that is currently available. The actual results will likely vary from the amounts set forth herein and such variations may be material.

Readers are cautioned that the foregoing list of assumptions and risk factors is not exhaustive. The forward-looking statements and FOFI contained herein are expressly qualified in their entirety by this cautionary statement. The forward-looking statements and FOFI included in this news release are made as of the date hereof and Decibel does not undertake any obligation to publicly update such forward-looking statements or FOFI to reflect new information, subsequent events or otherwise unless so required by applicable securities laws. The forward-looking statements and FOFI are made as of the date of this press release and the Company disclaims any intent or obligation to update any forward-looking statements or FOFI, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

SOURCE Decibel Cannabis Company Inc.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

AUSTIN, Texas, November 01, 2022–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the “Company” or “Anebulo”), today announced the appointment of Dr. Nat Calloway to its Board of Directors. Dr. Calloway will serve as a member of the Compensation Committee of the Board.

“We are very pleased to welcome Nat to the Anebulo Board,” said Simon Allen, Chief Executive Officer of Anebulo. “Nat’s deep experience within the investment community and strong healthcare background will be invaluable to Anebulo as we continue the development of ANEB-001.”

Dr. Calloway is an analyst and partner at 22NW, LP, a Seattle-based value fund specializing in small and microcap investments with a multi-year investment horizon, where he has been employed since June 2021. Dr. Calloway is the lead for 22NW, LP’s biotechnology, pharmaceutical and other healthcare investments, including Anebulo Pharmaceuticals, Inc. Prior to that, Dr. Calloway was the Associate Director of Healthcare Research for Edison Group from December 2015 to June 2021. He has a PhD in Chemistry and Chemical Biology from Cornell University, a Masters of Science in Chemistry from Columbia and completed a post-doctoral study in neuroscience at Weill Cornell Medical School. He has 10 scientific publications in the areas of physical chemistry, biochemistry and neuroscience.

About Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse disorder. Its lead product candidate, ANEB-001, is currently in a Phase 2 clinical trial (www.clinicaltrials.gov/ct2/show/NCT05282797) to evaluate its utility in reversing the negative effects of acute cannabinoid intoxication within one hour of administration. This trial is being run in the Netherlands by the Centre for Human Drug Research (CHDR). ANEB-001 is a competitive antagonist at the human cannabinoid receptor type 1 (CB1). For further information about Anebulo, please visit www.anebulo.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements, along with terms such as “anticipate,” “expect,” “intend,” “may,” “will,” “should” and other comparable terms, involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of Anebulo Pharmaceuticals and members of its management, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including risks attendant to developing, testing and commercializing the company’s product candidates, and those described in Anebulo Pharmaceutical’s most recent annual report on Form 10-K and in other periodic reports filed with the SEC, and that actual results may differ materially from those contemplated by such forward-looking statements. Except as required by federal securities law, Anebulo Pharmaceuticals undertakes no obligation to update or revise forward-looking statements to reflect changed conditions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221101006250/en/

Contacts

Anebulo Pharmaceuticals, Inc.
Scott Anderson
Head of Investor Relations and Public Relations
(858) 229-7063
[email protected]

Rex Merchant
Chief Financial Officer
(512) 598-0931
[email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

VANCOUVER, BC / ACCESSWIRE / October 6, 2022 / Lotus Ventures Inc. (CSE:J)(OTC PINK:LTTSF) (“Lotus” or the “Company“) a licensed cannabis producer, wholesaler, and the owner and operator of Lotus Cannabis Co., a premium-craft consumer brand in Canada, is pleased to announce the appointment of Albert Duwyn as its new Chairman of the Board of Directors (the “Directors”). The Directors held a meeting of appointment on September 30^th, 2022 and invited Albert Duwyn, an early supporter and shareholder of Lotus to become Chair of the Board. The Company will benefit from utilizing more of his extensive experience in its next phase of growth.

Albert is the past Owner and President of IRC Building Sciences Group Inc. In November 2020, Albert sold IRC to a Forensic Consulting Engineering firm in the US. Mr. Duwyn purchased IRC in 1991 and originally had 4 employees. Over the years he diversified the engineering service offerings, made key acquisitions, and grew the company to 14 offices and 170 employees across Canada while generating $25 million in annual sales.

Albert is no stranger to the agricultural business having grown up in Southwestern Ontario on a tobacco farm. His family has been active in the tobacco and cash crop business since 1927 and his next generation family members continue to do so. From an early age, Albert paid close attention to and participated with his father and brothers in the preparation, planning, growing, harvesting, processing, and selling of annual crops until leaving the farm at age 19 to pursue an education in architecture.

Albert is also an honours graduate of the Architectural Technology Program at Mohawk College and was honoured with an Alumni of Distinction Award last year. He has completed specialized courses at the International Institute of Building Envelope and the Roofing Industry Education Institute. He is a Registered Roof Consultant and a Fellow of IIBEC. Albert has served on numerous building rehabilitation assignments for both public and private sector clients and has been involved in the design and implementation of green roofs, solar and sustainable roof and building envelope assemblies.

Albert’s applicable experience in agriculture and construction will be beneficial for the Company and the whole team is excited about the future growth at Lotus.

British Columbia Direct Delivery and Production Update

Lotus is also pleased to announce that it has been approved for the recently authorized Direct Delivery program in British Columbia, previously discussed in the Company’s news release dated August 31, 2022. Lotus recently completed its 100^th consecutive harvest averaging 65,000 grams without any crop failures, and Lotus would like to give thanks to its talented cannabis production team in the North Okanagan, B.C.

ON BEHALF OF LOTUS VENTURES INC:
Lotus Ventures Inc.
“Dale McClanaghan”
Dale McClanaghan, President and CEO

About Lotus Ventures Inc.
Lotus Ventures Inc. (CSE:J) (OTC:LTTSF) is a BC-based licensed producer and wholesaler of premium cannabis. Lotus owns and operates the premium-craft consumer brand Lotus Cannabis Co. which has had its cannabis flower sold by wholesale partners in nine Canadian provinces to date, except Quebec. Lotus is an experienced cannabis cultivator with operations in the North Okanagan, BC, and the Lotus Cannabis Tranquil Elephantizer flower is currently sold in Ontario and B.C. while the Lotus Kalifornia is currently sold in Ontario in partnership with Kolab Project.

To invest in the Company, Lotus Ventures Inc. is listed on the Canadian Securities Exchange under the symbol J and on the OTC Markets under the symbol LTTSF.

For More Information:

President & CEO
Dale McClanaghan
604-644-9844

Investor Relations & Communications
Daniel McRobert
[email protected]
604-842-4625

To learn more, visit lotuscannabis.ca/updates or follow the Lotus Cannabis brand on social media.

Instagram: @lotuscannabisco
Twitter: @lotuscannabisco
LinkedIn: @lotuscannabisco
Facebook: @lotuscanna

Forward-Looking Information:
This document includes certain statements that are not descriptions of historical facts but are forward-looking statements. Such statements include, among others, those concerning our expected financial performance and strategic and operational plans, our future operating results, our expectations regarding the market for medical and recreational cannabis products, our expectations regarding the continued growth of the medical and recreational cannabis market, as well as all assumptions, expectations, predictions, intentions, or beliefs about future events. Users are cautioned that any such forward-looking statements are not guarantees of future performance and that a number of risks and uncertainties could cause our actual results to differ materially from those anticipated, expressed or implied in the forward-looking statements. These risks and uncertainties have not been documented or mentioned in this document nor other communications made by the company. The words “believe,” “expect,” “anticipate,” “project,” “targets,” “optimistic,” “intend,” “aim,” “will” or similar expressions are intended to identify forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The Company assumes no obligation and does not intend to update any forward-looking statements, except as required by law.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

SOURCE: Lotus Ventures, Inc.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Former Chief Legal Counsel at Aurora Brings Deep International Cannabis Regulatory Expertise

LAS VEGAS, NV / ACCESSWIRE / July 5, 2022 / Australis Capital Inc. (CSE:AUSA)(OTCQB:AUSAF) (“AUSA”, “AUDACIOUS”, or the “Company”), today announced that Jill Swainson has been appointed as member of the Board of Directors. Ms. Swainson will replace Mr. Avi Gellar who served as board member since November 2020, and who has resigned for personal reasons.

Hanoz Kapadia, Chairman of the Board, stated, “I want to thank Avi for his tremendous contributions to the Company since he joined the board, and I want to wish him well with his future endeavors. I also want to welcome Jill as our newest board member. Her experience will add to our governance practices. Her legal background in the international cannabis space will also be a great asset as the Company executes on its strategy.”

Terry Booth, CEO, added, “I am very pleased to welcome Jill to the board. Jill has been one of the leading legal lights in the cannabis sector, overseeing numerous transactions, international expansion, product launches and everything else. She brings a levelheaded and entrepreneurial approach that will serve AUDACIOUS and its shareholders well as we continue to grow the Company.”

Ms. Swainson added, “I am very pleased to take on this new role at AUDACIOUS, a company better positioned than many MSOs and other industry participants on the U.S. east coast, in particular New York and New Jersey. Combined with its existing high-quality assets in Nevada and California, as well as its international operations in Asia, AUDACIOUS is an exciting cannabis company and I look forward to working with Terry and the team to help bring the Company to the next level.”

Jill Swainson

A deeply experience legal professional, Ms. Swainson was 2019 Finalist for the Canadian General Counsel Awards – Dealmaker of the Year, as well as a two-Time Legal 500 General Counsel Powerlist Award. Ms. Swainson is an accomplished and forward-thinking executive with success as a General Counsel and strategic leader for a rapidly growing corporation in a highly regulated industry. She is recognized for a proven business acumen, a unifying style of leadership, deep compliance expertise, and a transformational influence on a company’s growth. Ms. Swainson joins the company fully equipped with the skills, knowledge and expertise to support an organization in achieving extraordinary results through people, process, policy and culture. Her expertise includes many capabilities important to the growth of AUDACIOUS, including Strategic Vision, Business Acumen, Leadership, Financial Management, Governance & Compliance, and Mergers & Acquisitions. Prior to Aurora, Ms. Swainson was Partner at Brownlee LLP.

About AUDACIOUS

AUDACIOUS is a next-generation MSO growing the cannabis industry of tomorrow from the ground up, led by industry pioneer Terry Booth and an accomplished management team with proven industry track records. With operations that range from providing industry-leading sustainable cultivation design and optimization to retail storefronts, growing flower in-house, and manufacturing award-winning brands, AUDACIOUS has products and solutions for everyone. Quickly expanding through innovative partnerships and collaborations, AUDACIOUS is forging the inclusive cannabis community of tomorrow, today. Learn more about AUDACIOUS here.

AUDACIOUS common shares trade on the CSE under the symbol “AUSA” and on the OTCQB under the symbol “AUSAF.”

Terry Booth, CEO
[email protected]

For further information, please contact:

For Investors:
Marc Lakmaaker
T: +1.647.289.6640
[email protected]

Neither the Canadian Securities Exchange nor its regulation services provider accepts responsibility for the adequacy or accuracy of this news release.

FORWARD-LOOKING STATEMENTS:

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute “forward-looking information” within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this news release. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except as required by applicable securities laws.

SOURCE: Australis Capital, Inc.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Industry leader Chris Ntoumenopoulos to support biotech Company’s mission to advance the delivery of psychedelic medicines

San Diego, California — (May 25, 2022) – Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the appointment of Chris Ntoumenopoulos to the Company’s Board of Directors.

“Chris is a seasoned, mission-driven advisor who supports organizations to excel beyond development and commercialization challenges,” said Jim Gilligan, Interim CEO and Chief Scientific Officer, Tryp Therapeutics. “He brings both financial and biotech experience as well as a global perspective to the Tryp team. His appointment is a milestone in Tryp’s growth strategy and mission to fulfill the vast demand for innovative health solutions for underserved indications.”

Ntoumenopoulos comes to Tryp with extensive experience in financial markets both in raising capital and corporate strategy. He currently serves as the Managing Director at 21 Corporate, an Australia-based Corporate Advisory firm which provides funding and corporate support for innovative companies and technologies. In addition, Ntoumenopoulos is a strategic investment adviser at Freeman Road, an investment group specializing in health and early-stage MedTech companies. Ntoumenopoulos also serves as Director of ResApp Diagnostics (RAP), a respiratory diagnostic company focusing on digital medicine, and as Director of ASX listed Race Oncology (RAC).

Ntoumenopoulos said, “Millions of individuals suffering from various forms of mental illness are in dire need of efficacious treatment alternatives, and Tryp is forging new ground with its tactical clinical approach. I look forward to collaborating with the team to further develop our novel drug pipeline and bring to market critical solutions to patients in need.”

About Tryp Therapeutics
Tryp Therapeutics is a clinical-stage biotechnology company focused on developing psilocybin-related molecules, including TRP-8803, for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-For-Neuropsychiatric Disorders (PFN) program is focused on the development of synthetic psilocybin-related molecules as a new class of drug for the treatment of binge eating, chronic pain, and other indications. The Company has begun enrolling patients in its Phase II trial for the treatment of binge eating disorder at the University of Florida and recently announced an upcoming Phase IIa clinical trial with the University of Michigan to evaluate TRP-8802 for fibromyalgia. TRP-8803 is a proprietary psilocybin-based product that uses a novel formulation and route of administration to potentially improve efficacy, safety and the patient experience. For more information, please visit www.tryptherapeutics.com.

Investor Relations:
Jim Gilligan, Interim CEO
Tryp Therapeutics
[email protected]

Media Relations:
Francesca DeMauro
KCSA Strategic Communications
[email protected]

Forward-Looking Information
Certain information in this news release constitutes forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans,” “targets,” “expects” or “does not expect,” “is expected,” “an opportunity exists,” “is positioned,” “estimates,” “intends,” “assumes,” “anticipates” or “does not anticipate” or “believes,” or variations of such words and phrases or state that certain actions, events or results “may,” “could,” “would,” “might,” “will” or “will be taken,” “occur” or “be achieved.” In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events.

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the “Risk Factors” section of Tryp’s final prospectus available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

• Flora Growth’s CEO Luis Merchan is named Chairman of the Board of Directors.
• Tim Leslie, Chairman of Flora’s Advisory Board, will join the Flora Board of Directors and audit committee.
• Changes to the Board of Directors signal the Company’s move toward becoming a U.S.-based issuer and will support Flora’s growth into new international markets.

MIAMI & TORONTO, March 17, 2022–(BUSINESS WIRE)–Flora Growth Corp. (NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, announced today changes to its Board of Directors (the “Board”) including the appointment of CEO Luis Merchan as Chairman of the Board as well as the addition of industry veteran Tim Leslie to the Board and audit committee. Merchan has replaced Bernie Wilson as Chairman of the Board. Wilson will remain in an advisory capacity for the remainder of 2022 and will provide strategic guidance on capital markets and international expansion. The changes to the Board will further position Flora as a U.S.-based issuer and is expected to increase the Company’s access to U.S-based investment.

Flora Chairman and CEO Luis Merchan has been focused on expanding the Company’s reach within the United States and abroad. Through his leadership, Flora has moved from the development stage to a full-scale international distributor and house of brands with operations in more than 12 countries. He has been pivotal in completing recently announced M&A transactions with leading hardware manufacturer Vessel and highly regarded wellness company JustCBD, solidifying the path to rapid growth.

“I am honored that our Board has entrusted me with this role, and I believe it is a testament to what we have built together thus far,” said Flora Growth CEO and newly appointed Chairman of the Board Luis Merchan. “Our Board has been incredibly supportive to date while always ensuring business decisions are in the best interest of our shareholders – and I am looking forward to continuing to work closely with them in this role.”

A Yale Law graduate, Tim Leslie has a strong pedigree of success, working with scaling companies including his two decades at Amazon. Leslie has been Chairman of the Company’s Advisory Board since the beginning of 2022, where he has utilized his years of experience as CEO of Leafly and as an Amazon executive to help counsel Flora’s leadership team. As Flora continues its rapid, global expansion, Leslie will play a critical role in navigating this hyper-growth phase. In addition to his role as board member, Leslie will also join the Company’s audit committee.

These appointments come as former Chairman of the Board, Bernie Wilson, steps down from his role and transitions to an advisory capacity to provide Merchan and the Board with strategic counsel, leveraging his insights and tenure in capital markets. “We want to thank Bernie for his commitment to the growth of Flora during this formative time for our company and look forward to continuing to work with him as we continue to grow,” added Merchan.

About Flora Growth Corp.

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands that is designed to deliver one of the most compelling customer experiences in the world, one community at a time. As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. Visit www.floragrowth.com or follow @floragrowthcorp on social [media] for more information.

Cautionary Statement Concerning Forward-Looking Statements

This document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: the size of markets for cannabis and cannabis products; the collaboration with third parties; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this document and other statements made from time to time by us or our representatives may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, or the forward-looking events discussed in this document and other statements made from time to time by us or our representatives not occurring, except as may be required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220317005405/en/

Contacts

Investor Relations:
Evan Veryard
[email protected]

Public Relations:
Cassandra Dowell
+1 (858) 264-6600
[email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

IRVINE, Calif., March 10, 2022–(BUSINESS WIRE)–WM Technology, Inc. (“WM Technology” or the “Company”) (Nasdaq: MAPS), the leading marketplace and technology solutions provider to the cannabis industry, today announced the appointment of Anthony Bay as the new Chairman of the Company’s Board of Directors. Effective immediately, Bay will succeed Chris Beals who was serving as the acting Chairman of the Board during the search to fill the role. Chris Beals will continue his role as a member of the board in addition to Chief Executive Officer of the Company.

“I could not be more excited to welcome Anthony to serve as Chairman of our Board of Directors,” said Chris Beals, CEO of WM Technology. “Since becoming a public company, our search for an independent chairperson has been driven by our commitment to be ‘best in class’ in corporate governance and to ensure we have the best advisors possible. Anthony understands the challenges and complexities associated with operating a two-sided marketplace, and brings with him a wealth of experience advising management teams, scaling hyper-growth technology companies and serving on a number of company boards, all of which will be critical as we continue to chart WM Technology’s path forward in the global cannabis marketplace.”

Bringing more than 20 years of board leadership experience to WM Technology, Bay is the founder and CEO of Techquity, an operating advisory firm of senior tech executives with deep experience growing and scaling companies. Techquity helps promising businesses scale from “one-to-one million users.” In addition to serving on boards of venture funded private companies during his career, Bay has served on several public boards in the US and Europe, including two as chairman. Bay has been a senior executive and led product groups at Apple, Microsoft and Amazon during periods of rapid, formative growth. At Microsoft, Bay was Corporate Vice President and a member of the executive staff with roles that included leadership of the company’s e-commerce and digital media technologies. While at Amazon, Bay served as Global Head of Amazon Video, and was responsible for the company’s digital video business globally.

“The opportunity to join WM Technology’s board comes at a time where the company has firmly established itself as the leading two-sided marketplace in the cannabis sector and is pairing that with a compelling suite of technology solutions for cannabis operators,” said Mr. Bay. “WM Technology is well positioned for growth, with the Company continuing to capitalize on the rapid expansion of the cannabis sector and the progress toward federal legalization. I look forward to working in partnership with Chris, the other board members, and the rest of the leadership team to capitalize on the immense opportunity the Company has before it.”

In his new role as Chairman of WM Technology, Bay will serve as a partner to Mr. Beals and the management team as they execute on a number of new growth opportunities including expansion into new legal cannabis markets, data monetization and broader brand offerings.

About WM Technology, Inc.

Founded in 2008, WM Technology operates the leading online cannabis marketplace with a comprehensive set of eCommerce and compliance software solutions sold to retailers and brands in the U.S. state-legal and Canadian cannabis markets. The Company’s mission is to power a transparent and inclusive global cannabis economy. We address the challenges facing both consumers seeking to understand cannabis products and businesses who serve cannabis users in a legally compliant fashion with our Weedmaps marketplace and WM Business software solutions. Over the past 13 years, we have grown the Weedmaps marketplace to become the premier destination for cannabis consumers to discover and browse information regarding cannabis and cannabis products, permitting product discovery and order-ahead for pickup or delivery by participating retailers. WM Business is a set of eCommerce-enablement tools designed to help our retailer and brand clients get the best out of their Weedmaps experience, while creating labor efficiency and managing their compliance needs.

WM Technology holds a strong belief in the power of cannabis and the importance of enabling safe, legal access to consumers worldwide. Since inception, WM Technology has worked tirelessly, not only to become the most comprehensive platform for consumers, but to build the software solutions that power businesses compliantly in the space, to advocate for legalization, social equity, and licensing in many jurisdictions, and to facilitate further learning through partnering with subject matter experts on providing detailed, accurate information about the plant.

Headquartered in Irvine, California, WM Technology supports remote work for all eligible employees. Visit us at www.weedmaps.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220310005885/en/

Contacts

Investor Relations:
[email protected]

Media:
Travis Rexroad
[email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

~35% of the Company’s Common Shares to Be Voluntarily Locked-Up for An Additional Twelve Months

SAN JOSE, Calif, Jan. 28, 2022 /CNW/ – TPCO Holding Corp. (“The Parent Company” or the “Company”) (NEO: GRAM.U) (OTCQX: GRAMF), a leading vertically-integrated California cannabis company, announced today that certain insiders (the “Insiders”) have individually voluntarily entered into a twelve-month extension of lock-up agreements with the Company (the “Lock-Up Agreements”) with respect to an aggregate of over 34 million shares of common stock (“Lock-up Shares”), or approximately 35% of the total issued and outstanding shares of common stock of the Company as of January 28, 2022.

Pursuant to the Lock-Up Agreements, the Insiders have agreed to lock up the common shares that they directly own or over which they exercise control or direction through January 28, 2023. The Insiders are comprised of the entire Board of Directors, Michael Auerbach, Carol Bartz, Al Foreman, Leland Hensch, Daniel Neukomm, Jeffry Allen, and Desiree Perez, and The Parent Company’s leadership team, including Troy Datcher, Chief Executive Officer, Mike Batesole, Chief Financial Officer, as well as additional senior team members.

“This voluntary extension demonstrates our Board of Directors’ and leadership team’s confidence in the long-term potential of our business,” said Troy Datcher, Chief Executive Officer of The Parent Company. “In the last year we have worked to expand our reach to over 80% of the adult population in California, triple our storefront presence, and deliver innovative new products for our customers. These initiatives support our goal to significantly expand our direct-to-consumer presence in California and provide customers with ease of access to high-quality products by meeting them where they are and how they like to shop.”

Mr. Datcher concluded, “With our well-known and robust branded products portfolio, expanded state-wide coverage and strong balance sheet, we believe this extended lock-up conveys the confidence we have in our ability to execute on the opportunities ahead in 2022 to generate long-term shareholder value.”

Under the terms of the Lock-Up Agreements, the Insiders have agreed, among other things, to not sell, pledge, assign, transfer, hypothecate or otherwise dispose of any of the Lock-up Shares, or enter into any swap, hedge or engage in any short-selling of the Lock-up Shares, without Company’ prior written consent. In addition to customary lock-up exceptions, the Lock-Up Agreements shall not apply to Insiders to the extent (i) any company with US cannabis operations (specifically operations that handle Tetrahydrocannabinol) is permitted to be listed on any senior US exchange, including the NYSE or Nasdaq, (ii) the trading price of The Parent Company’s common shares on the NEO Exchange Inc., or any other applicable stock exchange, exceeds US$10.00 at the close of any trading day or (iii) they cease to be a director, officer or employee of the Company.

About The Parent Company

Formed in January 2021, The Parent Company is a leading vertically integrated California cannabis company. The Company’s three manufacturing facilities provide access to high-quality cannabis, while its vast wholesale distribution network of more than 450 California dispensaries, a direct-to-consumer omnichannel platform, six consumer delivery hubs and eleven omni-channel retail locations, currently service approximately 80% of the largest legal cannabis market in the country. The Company’s curated product portfolio includes eight valuable and scalable brands, including Monogram, Caliva, Deli, Fun Uncle, and Mirayo, which set the tone for The Parent Company’s industry leadership in California and beyond.

In addition to its manufacturing infrastructure, consumer reach and cultural influence, The Parent Company is committed to using its resources and status to play a significant role in molding a more equitable cannabis industry. Its social equity ventures initiative, established by Chief Visionary Officer Shawn “JAY-Z” Carter, was created to break down the systematic barriers Black and other minority entrepreneurs face as they endeavor to secure meaningful participation, growth and leadership in the multibillion-dollar legal cannabis industry.

Shares of The Parent Company common stock are traded on NEO Exchange under the ticker symbol “GRAM.U” and on the OTCQX under the ticker symbol “GRAMF”.

Caution Regarding Cannabis Operations in the United States

Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. Cannabis remains a Schedule I drug under the U.S. Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute, or possess cannabis in the United States. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable U.S. federal money laundering legislation.

While the approach to enforcement of such laws by the federal government in the United States has trended toward non-enforcement against individuals and businesses that comply with medical or adult-use cannabis programs in states where such programs are legal, strict compliance with state laws with respect to cannabis will neither absolve The Parent Company of liability under U.S. federal law, nor will it provide a defense to any federal proceeding which may be brought against the Company. The enforcement of federal laws in the United States is a significant risk to the business of The Parent Company and any proceedings brought against the Company thereunder may adversely affect the Company’s operations and financial performance.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Names Eric C. Kutscher and Lawrence X. Taylor to Board of Directors; Adds a Combined 55-Plus Years of Experience Across Patient-Centered Healthcare, Leadership, M&A and Strategic Planning

PHOENIX, Jan. 4, 2022 /PRNewswire/ — Item 9 Labs Corp. (OTCQX: INLB) (the “Company”)—a vertically integrated cannabis dispensary franchisor and operator that produces premium, award-winning products—announced today that Eric C. Kutscher, Pharm. D., M.B.A., F.A.S.H.P., and Lawrence X. Taylor have been appointed to its Board of Directors.

“Eric and Lawrence have vastly different backgrounds that will enrich our foundation across several core growth areas of the company,” says Andrew Bowden, CEO of Item 9 Labs Corp.

Currently, the Company’s cannabis dispensary franchise brand, Unity Rd., has a franchisee-owned shop operating in Boulder, Colorado, as well as a corporate-owned shop opening soon in Adams County, Colorado, and agreements signed with nearly 20 partners who are in various stages of opening their Unity Rd. shops across Maine, Michigan, New Jersey, and Virginia, among other states. Item 9 Labs is the most in demand brand at more than 54% of Arizona’s dispensaries, according to LeafLink, and has earned more than 20 podium finishes in Arizona marijuana competitions. The Company is near completing development of its cultivation site in Nevada, recently started phase one of its master cultivation site development in Arizona and is seeking dispensary acquisitions to accelerate national growth.

Bowden added, “As we look ahead to expanding our products and franchise brands nationally, their depths of expertise will be a tremendous value.”

Kutscher and Taylor’s appointments demonstrate the Company’s focus on strengthening its corporate governance through more independent directors.

About Eric C. Kutscher:

Kutscher has 25-plus years of experience leading high-performing teams and is a thought leader in the delivery of patient-centered healthcare, research, academia, and leadership. He started his career in academic psychiatry and pharmacology and progressed to full clinical professor positions at three universities.

In 2013, Kutscher retired from his academic role to pursue healthcare executive opportunities and consulting. He has consulted with well-known companies such as SpotRx/MedAvail, MeMD, UAMC, UArizona/SinfroniaRx, TribalEM/Tribal Health, San Carlos Apache Healthcare, Pill Nurse, Walgreens, Connections Health Solutions, and various legal firms. Kutscher is currently the Senior Director for Clinical Operations and Pharmacy Services for Arizona Oncology Associates, the largest privately held Oncology practice in the state of Arizona, where he was hired to provide change leadership.

“What attracted me to Item 9 Labs Corp. was their vision and focus to bring credibility to the industry with very high-quality products as well as service to help people understand cannabis and all the potential therapeutic benefits beyond just a recreational high,” said Kutscher, noting that Unity Rd. appeals to consumers in both new and mature markets, leading with an education-first approach to guide individuals to the right products. “We have an opportunity to create industry standards and help people feel comfortable exploring cannabis as medicine.”

About Lawrence X. Taylor:

Taylor brings a diverse perspective to the boardroom, combining deep financial expertise, strategy, and governance to deliver thoughtful questions and insights that help drive informed decisions. As a C-level executive, advisor, and board member with more than 30 years of business experience, he has guided organizations through complex restructurings, acquisitions, corporate development activities and capital transactions totaling more than $15 billion. He possesses an extensive knowledge of finance, strategy and operations and has developed strategic, financial, operating and turnaround strategies across multiple industries including casino gaming, hospitality, manufacturing, aviation, real estate, and retail operations.

Lawrence currently serves on the boards of Barrie House Coffee and CLP Holdings III, LLC. At Barrie House Coffee, he chairs the M&A committee and serves on the Strategic Planning Committee. Previously, he served on the boards and committees (M&A, Strategic Planning, Restructuring, Finance and Compensation) of multiple companies. He has also served as a Board Member and Treasurer on the Finance and Compensation Committees for Sojourner Center and as a Board Member and Treasurer for E Tabs Manufacturing.

“Item 9 Labs Corp. is transforming the cannabis industry by utilizing the franchise model to drive retail growth and bring their products to new markets,” Taylor said. “It’s been exciting to watch their development and I’m honored to work with their leadership team to help bolster continued success.”

For more information on Item 9 Labs Corp. and its brands, visit https://investors.item9labscorp.com/.

About Item 9 Labs Corp.
Item 9 Labs Corp. (OTCQX: INLB) is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The award-winning Item 9 Labs brand specializes in best-in-class products and user experience across several cannabis categories. The company also offers a unique dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. Item 9 Labs brings the best industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation. The veteran management team combines a diverse skill set with deep experience in the cannabis sector, franchising, and the capital markets to lead a new generation of public cannabis companies that provide transparency, consistency, and well-being. Headquartered in Arizona, the company is currently expanding its operations space up to 640,000+ square feet on its 50-acre site, one of the largest properties in Arizona zoned to grow and cultivate flower. For additional information, visit item9labscorp.com.

Media Contact:
Item 9 Labs
Jayne Levy, VP of Communications
[email protected]

Investor Contact:
Item 9 Labs Corp.
[email protected]
800-403-1140

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.